Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral MedicalEDTXF 10 PS Ratio is 135.71 as of Jul. 15, 2026, which is 169% above its 10-year median of 50.42. GuruFocus rates EDTXF with a GF Score™ of 10/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Spectral Medical ranks worse than 98.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Spectral Medical's share price is $0.95.
Spectral Medical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01. Hence, Spectral Medical's PS Ratio for today is 135.71.
The historical rank and industry rank for Spectral Medical's PS Ratio or its related term are showing as below:
EDTXF'
s PS Ratio Range Over the Past 10 Years
Min: 11.18 Med: 50.42 Max: 188.89
Current: 145.97
During the past 13 years, Spectral Medical's highest PS Ratio was 188.89. The lowest was 11.18. And the median was 50.42.
EDTXF's PS Ratio is ranked worse than 98.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.78
vs EDTXF: 145.97
During the past 12 months, the average Revenue per Share Growth Rate of Spectral Medical was 12.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 14.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -10.10% per year.
During the past 13 years, Spectral Medical's highest 3-Year average Revenue per Share Growth Rate was 133.50% per year. The lowest was -44.70% per year. And the median was -10.70% per year.
Back to Basics: PS Ratio
Spectral Medical (OTCPK:EDTXF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Spectral Medical PS Ratio Related Terms
Spectral Medical PS Ratio Historical Data
* Premium members only.
The historical data trend for Spectral Medical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Spectral Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Spectral Medical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Spectral Medical's Share Price of today is $0.95. Spectral Medical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Spectral Medical (EDTXF) has a PS Ratio of 135.71 as of Jul. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Spectral Medical and its competitors. This is 169% above median its historical median of 50.42. Over the past decade, Spectral Medical's PS Ratio has ranged from 11.18 to 188.89. According to the industry distribution chart, Spectral Medical ranks #197 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 98.5%.
Is Spectral Medical's PS Ratio too high?
Spectral Medical's current PS Ratio of 135.71 is 169% above median its 10-year median of 50.42. Over the past 10 years, this metric has ranged from a low of 11.18 to a high of 188.89. The Medical Diagnostics & Research industry median PS Ratio is 2.78. Spectral Medical's value of 135.71 is 4781.7% above this industry median. Based on the distribution chart, Spectral Medical ranks #197 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Spectral Medical has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #197 out of 200 companies for PS Ratio. This places Spectral Medical in the lower half of its industry. The industry median PS Ratio is 2.78. Spectral Medical's value of 135.71 is 4781.7% above this benchmark. Historically, Spectral Medical's own PS Ratio has ranged from 11.18 to 188.89 over the past decade. While the company's 10-year median is 50.42 vs. the industry median of 2.78, Spectral Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.78, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spectral Medical's current PS Ratio of 135.71 is 4781.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Spectral Medical and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral Medical's current PS Ratio is 135.71, which is 169% above median its own 10-year median of 50.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (EDTXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $0.95 — trading 46.2% above its estimated fair value. The current PS Ratio is 135.71, which is 169% above median its 10-year median of 50.42 and 4781.7% above the Medical Diagnostics & Research industry median of 2.78. Spectral Medical's overall GF Score™ is 10/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Spectral Medical (EDTXF), the current PS Ratio is 135.71 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (EDTXF) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of $0.95 is trading 46.2% above its estimated GF Value™ of $0.65.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for EDTXF:
PS Ratio: 135.71 (169% above median its 10-year median of 50.42)
GF Value™: $0.65 vs. price of $0.95 (46.2% above fair value)
Industry Position: 4781.7% above the Medical Diagnostics & Research median (#197 of 200)
No single metric tells the full story. See the EDTXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
10GF Score
Get the complete analysis for EDTXF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDTXF has been successfully added to your 
